Literature DB >> 21999196

Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.

Berit Packert Jensen1, Rebecca Lee Roberts, Ritva Vyas, Gitte Bonke, David L Jardine, Evan James Begg.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: A single nucleotide polymorphism in ABCB1, which encodes P-glycoprotein, has retrospectively been associated with symptoms of nortriptyline-induced postural hypotension in depressed patients. This finding needs to be replicated in independent studies before recommendations regarding pharmacogenetic testing can be made. WHAT THIS STUDY ADDS: In a prospective study of healthy volunteers homozygous for ABCB1 (1236-2677-3435, TTT/TTT or CGC/CGC), a single dose of nortriptyline was administered, plasma exposure was determined and blood pressure and heart rate were monitored during posture change. No differences between ABCB1 haplotype groups were found in plasma exposure of nortriptyline and its active metabolites, E- and Z-10-hydroxynortriptyline. The heart rate response to posture change was increased with nortriptyline, whereas there was no difference in blood pressure response. However, no differences between haplotype groups were observed except that the pre dose heart rate response to standing was greater in the TTT than CGC homozygotes. The association between ABCB1 polymorphisms and nortriptyline-induced postural hypotension found in a previous study could not be confirmed. The results raise the possibility of a predisposition in heart rate response in the TTT homozygotes rather than an effect of nortriptyline. AIMS To investigate the influence of ABCB1 (1236-2677-3435) polymorphisms on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.
METHODS: Genetic screening of 67 healthy volunteers identified eight CGC homozygotes and nine TTT homozygotes of ABCB1 (1236-2677-3435), who were administered a single dose of nortriptyline 25 mg. Plasma exposure of nortriptyline and its active metabolites, E- and Z-10-hydroxynortriptyline, was determined over 72 h. Heart rate and blood pressure responses to posture change (active standing and passive head-up tilt) were measured continuously using finger plethysmography.
RESULTS: There were no differences in plasma exposure between ABCB1 haplotype groups, as the geometric mean (95% CI) AUC(0,72 h) ratios were 0.98 (0.94, 1.03), 1.02 (0.96, 1.09) and 0.95 (0.80, 1.10) for nortriptyline, E- and Z-10-hydroxynortriptyline, respectively. The pre dose heart rate response to standing was greater in the TTT than CGC homozygotes (mean (95% CI) difference 7.4 (1.5, 13.4) beats min(-1) , P = 0.02). At t(max) at 8 h post dose, nortriptyline increased the heart rate response to posture change in all subjects with mean (95% CI) Δ heart rate values of 7.4 (3.6, 11.3) beats min(-1) on active standing (P = 0.0009) and 4.8 (2.0, 7.6) beats min(-1) on head-up tilt (P = 0.002), but no difference was observed between haplotype groups. There was no difference in blood pressure response to posture change in either group.
CONCLUSION: The association between ABCB1 polymorphisms and nortriptyline-induced postural hypotension found in the previous study could not be confirmed. The results raise the possibility of a predisposition in heart rate response in the TTT homozygotes rather than an effect of nortriptyline.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21999196      PMCID: PMC3376438          DOI: 10.1111/j.1365-2125.2011.04126.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.

Authors:  J-B Woillard; J-P Rerolle; N Picard; A Rousseau; A Guillaudeau; E Munteanu; M Essig; M Drouet; Y Le Meur; P Marquet
Journal:  Clin Pharmacol Ther       Date:  2010-05-26       Impact factor: 6.875

2.  Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption.

Authors:  M Uhr; T Steckler; A Yassouridis; F Holsboer
Journal:  Neuropsychopharmacology       Date:  2000-04       Impact factor: 7.853

3.  Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls.

Authors:  Manfred Uhr; Markus T Grauer; Alexander Yassouridis; Martin Ebinger
Journal:  J Psychiatr Res       Date:  2006-01-04       Impact factor: 4.791

4.  The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

Authors:  A Gaedigk; S D Simon; R E Pearce; L D Bradford; M J Kennedy; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

5.  Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.

Authors:  T K Bergmann; C Brasch-Andersen; H Gréen; M Mirza; R S Pedersen; F Nielsen; K Skougaard; J Wihl; N Keldsen; P Damkier; L E Friberg; C Peterson; W Vach; M O Karlsson; K Brosen
Journal:  Pharmacogenomics J       Date:  2010-04-06       Impact factor: 3.550

6.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

Review 7.  ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research.

Authors:  G D Leschziner; T Andrew; M Pirmohamed; M R Johnson
Journal:  Pharmacogenomics J       Date:  2006-09-12       Impact factor: 3.550

8.  Comparison of risk of orthostatic hypotension in elderly depressed hypertensive women treated with nortriptyline and thiazides versus elderly depressed normotensive women treated with nortriptyline.

Authors:  M Z Scalco; O P de Almeida; D T Hachul; S Castel; J Serro-Azul; M Wajngarten
Journal:  Am J Cardiol       Date:  2000-05-01       Impact factor: 2.778

9.  Fast and sensitive LC-MS/MS assay for quantification of nortriptyline and its active metabolites E- and Z-10-hydroxynortriptyline in human plasma.

Authors:  Gitte Bonke; Berit P Jensen
Journal:  Bioanalysis       Date:  2010-09       Impact factor: 2.681

10.  The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites.

Authors:  Thomas Broeng Ejsing; Jørgen Hasselstrøm; Kristian Linnet
Journal:  Drug Metabol Drug Interact       Date:  2006
View more
  8 in total

1.  A common polymorphism in the ABCB1 gene is associated with side effects of PGP-dependent antidepressants in a large naturalistic Dutch cohort.

Authors:  P M Bet; E C Verbeek; Y Milaneschi; D B M Straver; T Uithuisje; M R Bevova; J G Hugtenburg; P Heutink; B W J H Penninx; W J G Hoogendijk
Journal:  Pharmacogenomics J       Date:  2015-05-19       Impact factor: 3.550

Review 2.  Distal tubule basolateral potassium channels: cellular and molecular mechanisms of regulation.

Authors:  Oleg Palygin; Oleh Pochynyuk; Alexander Staruschenko
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-09       Impact factor: 2.894

Review 3.  Mechanisms of antidepressant resistance.

Authors:  Wissam El-Hage; Samuel Leman; Vincent Camus; Catherine Belzung
Journal:  Front Pharmacol       Date:  2013-11-22       Impact factor: 5.810

4.  Nortriptyline, a tricyclic antidepressant, inhibits voltage-dependent K+ channels in coronary arterial smooth muscle cells.

Authors:  Sung Eun Shin; Hongliang Li; Han Sol Kim; Hye Won Kim; Mi Seon Seo; Kwon-Soo Ha; Eun-Taek Han; Seok-Ho Hong; Amy L Firth; Il-Whan Choi; Young Min Bae; Won Sun Park
Journal:  Korean J Physiol Pharmacol       Date:  2017-02-21       Impact factor: 2.016

5.  ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.

Authors:  A B Singh; C A Bousman; C H Ng; K Byron; M Berk
Journal:  Transl Psychiatry       Date:  2012-11-27       Impact factor: 6.222

6.  ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib.

Authors:  Douglas Vivona; Luciene Terezina Lima; Alice Cristina Rodrigues; Carolina Tosin Bueno; Greyce Kelly Steinhorst Alcantara; Luiza Saldanha Ribeiro Barros; Vania Tiestsche DE Moraes Hungria; Carlos Sérgio Chiattone; Maria DE Lourdes Lopes Ferrari Chauffaille; Elvira Maria Guerra-Shinohara
Journal:  Oncol Lett       Date:  2014-02-07       Impact factor: 2.967

Review 7.  A proposed role for efflux transporters in the pathogenesis of hydrocephalus.

Authors:  Satish Krishnamurthy; Michael D Tichenor; Akhila G Satish; David B Lehmann
Journal:  Croat Med J       Date:  2014-08-28       Impact factor: 1.351

Review 8.  Nanomedicine applications in women's health: state of the art.

Authors:  Oliver Lloyd-Parry; Charlotte Downing; Eisa Aleisaei; Celine Jones; Kevin Coward
Journal:  Int J Nanomedicine       Date:  2018-03-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.